SuperworthBristol-Myers Squibb Company BMY
Drug Manufacturers - General, Healthcare
$59.70
+0.18%
- Market cap
- $122B
- PE
- 13.1×
- 10y median 19.9×
- Forward PE
- Price to sales
- 2.5×
- EV/EBIT
- 12.1×
- Revenue, 12 months
- $49.2B
- +3% on a year ago
- Net margin
- 18.9%
- Free cash flow yield
- 9.4%
Bristol-Myers Squibb trades at 13.1× trailing earnings, cheaper than 94% of the last ten years. Revenue was $49.2B over the last twelve months, up 3% on a year earlier with a 19% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $11.5B | $11.9B | $12.2B | $11.9B | $12.3B+8% | $11.2B−6% | $12.3B+1% | $12.2B+3% | $12.5B+1% | $11.5B+3% | $13B+6% | |
| Cost of revenue | $2.7B | $2.9B | $3.3B | $3B | $4.8B+75% | $3B+3% | $3.4B+3% | $3.4B+16% | $4.1B−15% | $3.4B+13% | $3.7B+11% |
| Gross profit | $8.7B | $8.9B | $8.9B | $8.9B | $7.5B−14% | $8.2B−9% | $8.9B−0% | $8.8B−2% | $8.4B+12% | $8.1B−1% | $9.2B+4% |
| R&D | $2.5B | $2.7B | $2.9B | $2.4B | $3.2B+29% | $2.3B−16% | $2.6B−11% | $2.5B+7% | $2.6B−19% | $2.6B+17% | $3B+15% |
| SG&A | $2.1B | $2.4B | $1.9B | $2B | $2.1B+3% | $1.6B−33% | $1.7B−11% | $1.8B−10% | $2.2B+2% | $1.6B+2% | $1.8B+7% |
| $2B | $1.5B | $2.6B | $2.3B | $2.5B+30% | $3.5B+128% | $3.8B+46% | $3.6B+59% | $2.8B+11% | $3.4B−4% | $4.1B+8% | |
| Interest expense | $316M | $425M | $521M | $505M | $496M+57% | $494M+16% | $485M−7% | $480M−5% | $432M−13% | $411M−17% | $407M−16% |
| Pre-tax income | $1.7B | −$11.5B | $1.3B | $1.7B | $175M−90% | $3B | $1.8B+38% | $3.1B+86% | $1.5B+740% | $3.2B+9% | $4.1B+131% |
| −$88M | $392M | −$398M | $461M | $99M | $509M+30% | $460M | $919M+99% | $384M+288% | $561M+10% | $770M+67% | |
| Net income | $1.8B | −$11.9B | $1.7B | $1.2B | $72M−96% | $2.5B | $1.3B−22% | $2.2B+82% | $1.1B+1410% | $2.7B+9% | $3.3B+153% |
| $0.87 | −$5.89 | $0.83 | $0.60 | $0.04−96% | $1.20 | $0.64−23% | $1.08+80% | $0.53+1401% | $1.31+9% | $1.62+153% | |
| 2B | 2B | 2B | 2B | 2B+0% | 2B+1% | 2B+0% | 2B+0% | 2B+0% | 2B+0% | 2B+1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Drug Manufacturers - General within ten times Bristol-Myers Squibb's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BMYBristol-Myers Squibb Company | $122B | 13.1× | 19.9× | 2.5× | +3% | 18.9% | |
| PFEPfizer Inc. | $159.6B | 36.8× | 16.3× | 2.5× | −0% | 6.8% | |
| AMGNAmgen Inc. | $223.3B | 25.7× | 21.0× | 5.9× | +9% | 23.0% | |
| MRKMerck & Co., Inc. | $352.3B | 114× | 25.7× | 5.3× | +5% | 4.8% | |
| BIIBBiogen Inc. | $32.8B | 39.3× | 16.1× | 3.3× | +0% | 8.3% | |
| ABBVAbbVie Inc. | $479.5B | 76.7× | 27.5× | 7.4× | +10% | 9.8% | |
| JNJJohnson & Johnson | $622.8B | 29.9× | 24.2× | 6.4× | +8% | 21.5% | |
| LLYEli Lilly and Company | $1.1T | 39.9× | 41.3× | 14.0× | +50% | 33.5% | |
| Peer median | $352.3B | 39.3× | 24.2× | 5.9× | +8% | 9.8% |
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .